Drug Combination Details
| General Information of the Combination (ID: C83616) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Erlotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Head and neck cancer
[ICD-11: 2D42]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Tu 177 | CVCL_4913 | Laryngeal squamous cell carcinoma | Homo sapiens | ||
| Tu 212 | CVCL_4915 | Head and neck squamous cell carcinoma | Homo sapiens | |||
| MDA-886Ln | CVCL_6987 | Laryngeal squamous cell carcinoma | Homo sapiens | |||
| SqCC/Y1 | CVCL_0551 | Oral cavity squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | Animal models were constructed by injecting Tu212 cells (2*106) into the right flank of nude mice (athymic nu/nu). | |||||
| Experimental
Result(s) |
The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Tu 177 | CVCL_4913 | Laryngeal squamous cell carcinoma | Homo sapiens | ||
| Tu 212 | CVCL_4915 | Head and neck squamous cell carcinoma | Homo sapiens | |||
| MDA-1986LN | CVCL_AT80 | Oral cavity squamous cell carcinoma | Homo sapiens | |||
| MDA-886Ln | CVCL_6987 | Laryngeal squamous cell carcinoma | Homo sapiens | |||
| SqCC/Y1 | CVCL_0551 | Oral cavity squamous cell carcinoma | Homo sapiens | |||
| 38 | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
Erlotinib treatment activates p53, which plays a critical role in synergistic growth inhibition by erlotinib and EGCG via inhibiting nuclear factor-kappaB signaling pathway. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | BCL2L11 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Tu 686 | CVCL_4916 | Laryngeal squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. | |||||
